Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.
Martin-Algarra S, Hinshelwood R, Mesnage S, Cebon J, Ferrucci PF, Aglietta M, Neyns B, Chiarion-Sileni V, Lindsay CR, Del Vecchio M, Linardou H, Merelli B, Tonini G, Atkinson V, Freivogel K, Stein D, Dalland L, Lau M, Legenne P, Queirolo P, Millward M. Martin-Algarra S, et al. Among authors: aglietta m. Melanoma Res. 2019 Oct;29(5):527-532. doi: 10.1097/CMR.0000000000000608. Melanoma Res. 2019. PMID: 31095039
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P. Chiarion Sileni V, et al. Among authors: aglietta m. J Exp Clin Cancer Res. 2014 Apr 4;33(1):30. doi: 10.1186/1756-9966-33-30. J Exp Clin Cancer Res. 2014. PMID: 24708900 Free PMC article. Clinical Trial.
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P. Ascierto PA, et al. Among authors: aglietta m. J Transl Med. 2014 May 7;12:116. doi: 10.1186/1479-5876-12-116. J Transl Med. 2014. PMID: 24885479 Free PMC article.
Treatment of metastatic melanoma: a multidisciplinary approach.
Fava P, Astrua C, Sanlorenzo M, Ribero S, Brizio M, Filippi AR, Marra E, Picciotto F, Sangiolo D, Carnevale-Schianca F, Aglietta M, Sandrucci S, Ricardi U, Caliendo V, Quaglino P, Fierro MT. Fava P, et al. Among authors: aglietta m. G Ital Dermatol Venereol. 2017 Jun;152(3):241-261. doi: 10.23736/S0392-0488.17.05633-4. Epub 2017 Mar 14. G Ital Dermatol Venereol. 2017. PMID: 28290625 Review.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Overman MJ, et al. Among authors: aglietta m. J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20. J Clin Oncol. 2018. PMID: 29355075 Free article.
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.
Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Nannini M, et al. Among authors: aglietta m. Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19. Ther Adv Med Oncol. 2017. PMID: 29449894 Free PMC article.
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV. Atkinson V, et al. Among authors: aglietta m. Melanoma Res. 2020 Jun;30(3):261-267. doi: 10.1097/CMR.0000000000000654. Melanoma Res. 2020. PMID: 31895752
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
Atkinson VG, Quaglino P, Aglietta M, Del Vecchio M, Depenni R, Consoli F, Bafaloukos D, Ferrucci PF, Tulyte S, Krajsová I, Ascierto PA, Gueli R, Arance A, Gogas H, Banerjee H, Saliba T, de Jong E, Neyns B. Atkinson VG, et al. Among authors: aglietta m. Cancers (Basel). 2021 May 18;13(10):2466. doi: 10.3390/cancers13102466. Cancers (Basel). 2021. PMID: 34070224 Free PMC article.
469 results